<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006098</url>
  </required_header>
  <id_info>
    <org_study_id>00-031</org_study_id>
    <secondary_id>CDR0000068105</secondary_id>
    <secondary_id>NCI-G00-1827</secondary_id>
    <nct_id>NCT00006098</nct_id>
  </id_info>
  <brief_title>PS-341 in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase I Study of PS-341 in Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      tumor cell growth.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have&#xD;
      hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose and dose-limiting toxicity of PS-341 in&#xD;
      patients with hematologic malignancies. II. Determine the pharmacodynamics of this drug in&#xD;
      these patients. III. Determine response to this drug in these patients. IV. Determine the&#xD;
      correlation between response of malignancies and proteasome inhibition and apoptosis in&#xD;
      peripheral blood mononuclear cells (PBMC) of these patients. V. Determine the correlation&#xD;
      between therapy toxicity and proteasome inhibition and apoptosis in PBMC of these patients.&#xD;
      VI. Determine the effect of this drug on other molecular markers (i.e., BCL-2 in follicular&#xD;
      lymphoma patients and t9;22/BCR/ABL in chronic lymphocytic leukemia patients). VII. Determine&#xD;
      the correlation between interleukin-6 serum levels in multiple myeloma patients and drug&#xD;
      dosing, toxicity of therapy, extent of protease inhibition, response to therapy, and&#xD;
      apoptosis in PBMC of these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients receive PS-341 IV over 30&#xD;
      minutes on days 1, 4, 8, 11, 15, 18, 22, and 25 followed by a 2-week rest. Treatment repeats&#xD;
      every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6&#xD;
      patients receive escalating doses of PS-341 until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting&#xD;
      toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed hematologic malignancy including: Acute&#xD;
        myeloid leukemia Chronic myelogenous leukemia Acute lymphoblastic leukemia Chronic&#xD;
        lymphocytic leukemia Hodgkin's disease Non-Hodgkin's lymphoma Multiple myeloma&#xD;
        Myelodysplastic syndrome subtypes: Refractory anemia with excess blasts (RAEB) RAEB in&#xD;
        transformation Refractory to standard treatment or no curative therapy available Measurable&#xD;
        disease Not eligible for higher priority study&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At&#xD;
        least 6 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least&#xD;
        1,000/mm3 Platelet count at least 50,000/mm3 Hematocrit at least 25% Hepatic: SGOT and SGPT&#xD;
        less than 2.5 times upper limit of normal (ULN) Bilirubin less than 1.5 times ULN Renal:&#xD;
        Creatinine clearance greater than 50 mL/min Cardiovascular: No acute ischemia or new&#xD;
        conduction system abnormalities by EKG No prior myocardial infarction within past 6 months&#xD;
        No New York Heart Association class III or IV congestive heart failure Other: Febrile&#xD;
        episodes up to 38.5 degrees C due to tumor fever allowed No concurrent active infection No&#xD;
        grade 1 or greater National Cancer Institute common toxicity criteria No serious medical or&#xD;
        psychiatric condition that would preclude study Not pregnant or nursing Negative pregnancy&#xD;
        test Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy No&#xD;
        concurrent immunotherapy Chemotherapy: At least 4 weeks since prior chemotherapy No other&#xD;
        concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks&#xD;
        since prior radiotherapy No concurrent radiotherapy Surgery: At least 2 weeks since prior&#xD;
        major surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Soignet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>March 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2004</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

